The "HOHMS Paradigm" posits that treatment regimens for lung cancer patients should be based on a high level of histological and molecular stratification to maximize response rates and survival prolongation, and minimize toxicity.
Histological stratification should be based on subtypes recognized in the 2004 revision of the World Health Organization (WHO) lung tumor typing system [REF].